EverSource Wealth Advisors LLC Acquires 69 Shares of Danaher Co. (NYSE:DHR)

EverSource Wealth Advisors LLC boosted its holdings in shares of Danaher Co. (NYSE:DHR) by 5.3% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,366 shares of the conglomerate’s stock after acquiring an additional 69 shares during the quarter. EverSource Wealth Advisors LLC’s holdings in Danaher were worth $337,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in DHR. DekaBank Deutsche Girozentrale lifted its position in shares of Danaher by 4.3% in the 1st quarter. DekaBank Deutsche Girozentrale now owns 710,636 shares of the conglomerate’s stock worth $176,325,000 after purchasing an additional 29,081 shares during the period. Cambridge Trust Co. lifted its position in shares of Danaher by 17.5% in the 1st quarter. Cambridge Trust Co. now owns 87,500 shares of the conglomerate’s stock worth $21,850,000 after purchasing an additional 13,062 shares during the period. Soltis Investment Advisors LLC acquired a new position in shares of Danaher in the 1st quarter worth approximately $290,000. Cetera Advisor Networks LLC lifted its position in shares of Danaher by 6.3% in the 1st quarter. Cetera Advisor Networks LLC now owns 72,454 shares of the conglomerate’s stock worth $18,093,000 after purchasing an additional 4,266 shares during the period. Finally, Cetera Advisors LLC lifted its position in shares of Danaher by 44.3% during the 1st quarter. Cetera Advisors LLC now owns 27,346 shares of the conglomerate’s stock valued at $6,829,000 after acquiring an additional 8,389 shares during the period. 79.05% of the stock is owned by institutional investors.

Insider Activity at Danaher

In related news, Director Linda Filler sold 3,928 shares of the stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $279.50, for a total transaction of $1,097,876.00. Following the completion of the transaction, the director now owns 41,149 shares in the company, valued at $11,501,145.50. The transaction was disclosed in a document filed with the SEC, which is available through this link. In other Danaher news, Director Linda Filler sold 3,928 shares of the stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $279.50, for a total transaction of $1,097,876.00. Following the completion of the transaction, the director now owns 41,149 shares in the company, valued at $11,501,145.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Rainer Blair sold 19,085 shares of the stock in a transaction dated Tuesday, May 14th. The stock was sold at an average price of $255.00, for a total transaction of $4,866,675.00. Following the completion of the sale, the chief executive officer now directly owns 115,995 shares in the company, valued at $29,578,725. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 113,174 shares of company stock worth $29,775,644. 11.10% of the stock is owned by company insiders.

Analyst Ratings Changes

A number of research analysts recently issued reports on the stock. Robert W. Baird boosted their target price on shares of Danaher from $271.00 to $278.00 and gave the company an “outperform” rating in a research report on Wednesday, July 24th. SVB Leerink boosted their target price on shares of Danaher from $275.00 to $280.00 and gave the company an “outperform” rating in a research report on Wednesday, July 24th. Bank of America boosted their target price on shares of Danaher from $270.00 to $275.00 and gave the company a “neutral” rating in a research report on Wednesday, July 24th. Jefferies Financial Group assumed coverage on shares of Danaher in a research report on Monday, June 3rd. They set a “buy” rating and a $295.00 target price on the stock. Finally, Royal Bank of Canada boosted their target price on shares of Danaher from $297.00 to $300.00 and gave the company an “outperform” rating in a research report on Wednesday, July 24th. Six analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $276.88.

Danaher Stock Down 1.4 %

Shares of NYSE DHR traded down $4.01 during trading on Friday, hitting $276.75. The stock had a trading volume of 3,108,808 shares, compared to its average volume of 3,183,765. Danaher Co. has a 12 month low of $182.09 and a 12 month high of $281.70. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.43 and a quick ratio of 1.04. The company has a market capitalization of $199.87 billion, a PE ratio of 46.91, a PEG ratio of 4.62 and a beta of 0.83. The firm has a fifty day moving average of $256.29 and a two-hundred day moving average of $250.77.

Danaher (NYSE:DHR) last posted its earnings results on Tuesday, July 23rd. The conglomerate reported $1.72 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.57 by $0.15. The firm had revenue of $5.74 billion during the quarter, compared to analyst estimates of $5.59 billion. Danaher had a net margin of 16.94% and a return on equity of 11.06%. The business’s revenue was down 2.9% compared to the same quarter last year. During the same quarter in the prior year, the business posted $2.05 EPS. As a group, equities research analysts forecast that Danaher Co. will post 7.59 EPS for the current fiscal year.

Danaher Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, July 26th. Investors of record on Friday, June 28th were given a dividend of $0.27 per share. The ex-dividend date of this dividend was Friday, June 28th. This represents a $1.08 annualized dividend and a yield of 0.39%. Danaher’s payout ratio is currently 18.31%.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.